Abstract: This is a 96-week prospective cohort study of antiretroviral therapy (ART)–naive HIV-infected adults and matched healthy controls to assess progression of carotid intima media thickness (CIMT) and its relationship to inflammation. Median common carotid artery (CCA) CIMT increased significantly but similarly in both groups [CCA: 0.02 (interquartile range: 0–0.05); P < 0.01 within HIV-infected adults vs. 0.01 (0–0.05) mm; P < 0.01 within controls; and P = 0.83 between groups]. Change in bulb CIMT yielded similar results. Independent predictors of CCA CIMT progression in HIV-infected adults were higher systolic blood pressure, total cholesterol, and high sensitivity C-reactive protein. Independent predictors of bulb CIMT progression were higher non–high-density lipoprotein cholesterol and high sensitivity C-reactive protein. Other inflammation markers were not associated with CIMT progression.
*Case Western Reserve University School of Medicine, Cleveland, OH;
†Department of Medicine, Division of Infectious Disease, MetroHealth Medical Center, Cleveland, OH;
‡Department of Medicine, Division of Cardiovascular Medicine, University Hospitals Harrington Heart and Vascular Institute, Cleveland, OH; and
§Department of Pediatrics, Division of Infectious Disease, University Hospitals Case Medical Center, Cleveland, OH.
Correspondence to: Grace A. McComsey, MD, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106 (e-mail: firstname.lastname@example.org).
This study was sponsored by Bristol Myers Squibb.
The results of this study were previously presented at the 20th Conference on Retroviruses and Opportunistic infections, March 3–6, 2013, Atlanta, GA.
C.T.L. has received research grant support from Bristol-Myers Squibb and the Medtronic Foundation. T.L.C. serves on the DSMB of Prairie Education and Research Cooperative. G.A.M. has served as a scientific advisor or speaker for Bristol-Myers Squibb, Merck, and Gilead Sciences; has received research grants from Bristol-Myers Squibb, GlaxoSmithKline, and Gilead Sciences; and is currently serving as the DSMB Chair for a Pfizer-sponsored study.
Received November 03, 2013
Accepted November 16, 2013